Merck KGaA

MicroDose achieves clinical milestone in its collaboration with Merck

pharmaceutical-business-review.com     15 hrs ago          

MicroDose Technologies has announced that the first clinical milestone in its collaboration with Merck & Co, through a Merck affiliate, has been achieved, triggering the first payment under the global license agreement for...                    

comments

sciencedaily.com: ScienceDaily: Your source for the latest research news and science breakthroughs -- updated daily sciencedaily.com

People With Heart Disease Still Have Trouble Controlling Blood Lipid Levels

sciencedaily.com     18 hrs ago   1 related          

ScienceDaily (Aug. 7, 2008) — Despite some improvements to lower “bad” cholesterol levels, people with cardiovascular diseases still need to do a better job controlling overall blood lipid levels, according to a UC Irvine Heart...                    

comments

Ariad to receive $2.5 million from partner Merck

ibtimes.com     yesterday   3 related          

CAMBRIDGE, Mass. - Ariad Pharmaceuticals Inc. said Wednesday it will receive a $2.5 million payment from partner Merck & Co. for moving a cancer drug into midstage clinical trials. The drug, called deforolimus, is being studied...                    

comments

                   

Mylan swings to 2Q loss on acquisition costs (AP)

yahoo.com     yesterday   5 related          

Wednesday August 6, 8:48 am ET Mylan takes 2nd-quarter loss, but sales more than double after Merck generic buyout PITTSBURGH (AP) -- Generic drug maker Mylan Inc. said Wednesday it swung to a loss after buying the generics...                    

comments

Phase Forward, Lilly Extend Multi-Year Agreement

tmcnet.com     yesterday          

WALTHAM, Mass. --(Business Wire)-- Phase Forward (NASDAQ: PFWD), a leading provider of data management solutions for clinical trials and drug safety, today announced a multi-year extension agreement with Eli Lilly and Company...                    

comments

                   

BioMarin Pharmaceutical, Inc. Q2 2008 Earnings Call Transcript

seekingalpha.com     yesterday   2 related          

posted on: August 06, 2008 | about stocks: BMRN Executives Eugenia Shen - Results may differ materially depending on the progress of BioMarin's product programs, actions of regulatory authorities, availability of capital,...                    

comments

                   

Pfizer Selects Alexandria Real Estate Equities' Mission Bay Life Science Cluster as the Home for Its

pharmiweb.co.uk     yesterday   7 related          

Mayor Gavin Newsom Held Ground Breaking Press Conference Today at The Alexandria Center for Science and Technology at Mission Bay, Recognized as a World-Class Cluster Destination for Life Sciences - Alexandria Real Estate...                    

comments

genengnews.com: Genetic Engineering genengnews.com

Dynavax and Merck & Co., Inc. Announce Phase 3 Trial with Investigational Hepatitis B Vaccine...

genengnews.com     Aug 5, 2008   2 related          

News source: Business Wire Dynavax Technologies Corporation and Merck & Co., Inc. announced today top-line immunogenicity results from a Phase 3 clinical trial comparing HEPLISAV(TM), an investigational hepatitis B virus (HBV)...                    

comments

                   
earthtimes.org: CAMBRIDGE, Mass. - ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) today reported financial results for the second quarter and six months ended June 30, 2008, provided an update on corporate developments and announced changes in its senior management team. earthtimes.org

Dynavax Announces Second Quarter 2008 Financial Results : Revenues Increase for Quarter, Per...

prweb.com     Aug 5, 2008   460 related          

BERKELEY, Calif. August 5, 2008 -- Dynavax Technologies Corporation (Nasdaq:DVAX) today reported financial results for the second quarter and six months ended June 30, 2008. The increase in revenues for the second quarter and...                    

comments (1)

ISENTRESS(R) (raltegravir), Merck's First in Class Integrase Inhibitor, Reduced HIV Viral Load...

yahoo.com     Aug 5, 2008   1 related          

WHITEHOUSE STATION, N.J.----ISENTRESS® , Merck & Co., Inc.'s first-in-class integrase inhibitor, in combination with two other anti-HIV medicines, reduced HIV viral load to undetectable levels in 83 percent of previously...                    

comments

1 2 3 4 5 next »